Aspira Women's Health Inc. (AWH): history, ownership, mission, how it works & makes money

A Brief History of Aspira Women's Health Inc. (AWH)

Formation and Initial Focus

Aspira Women's Health Inc. was formed in 2008, originally as a subsidiary of the biotechnology company Aspira Biosciences. The focus was largely on women's health, particularly in the realm of ovarian cancer screening and diagnostics.

Key Developments in the First Decade

In 2014, Aspira launched its first product, the Ova1 test, aimed at assessing the risk of malignancy in ovarian tumors. The test received its FDA approval and was intended for use in pre-operative assessment.

Financial Growth and Market Position

By 2020, Aspira Women's Health reported revenues of approximately $4.2 million. The increase from the previous year demonstrated a growth trajectory due to expanding clinical studies and partnerships.

Recent Developments and Innovations

In 2021, the company introduced OvaWatch, a new product designed to monitor women with an increased risk of ovarian cancer. The offering aimed to complement the existing Ova1 test and further solidified the company’s foothold in the women's health sector.

Strategic Partnerships and Investments

Aspira Women's Health has garnered investments and strategic partnerships over the years, particularly focusing on collaborations with leading healthcare organizations. As of 2021, the company raised $20 million in a public offering to fund ongoing research and development.

Stock Performance and Market Capitalization

As of October 2023, Aspira Women’s Health Inc. trades under the ticker symbol AWH on the NASDAQ. The market capitalization stood at approximately $65 million.

Future Outlook

Aspira Women’s Health is focused on enhancing its diagnostics portfolio and expanding its market reach. The company aims to leverage its proprietary technologies to capture a larger share of the diagnostics and monitoring market within women's health.

A Who Owns Aspira Women's Health Inc. (AWH)

Corporate Ownership Structure

As of the latest available data, Aspira Women's Health Inc. (AWH) is a publicly traded company on the NASDAQ under the ticker symbol "AWH." The ownership is divided among institutional investors, retail investors, and insiders.

Major Institutional Shareholders

The following are some of the significant institutional shareholders of Aspira Women's Health Inc.:

Insider Ownership Breakdown

Insider ownership plays a vital role in the governance of the company. Here’s a breakdown of the insider ownership:

Recent Share Performance

Aspira Women's Health Inc. has experienced notable fluctuations in its stock price over the past year, affecting ownership dynamics.

Market Trends and Analysis

The women's health sector, which Aspira Women's Health operates within, has shown growth potential, resulting in increased interest among investors.

Voting Power Distribution

Understanding the voting power among shareholders is crucial for determining the decision-making dynamics within Aspira Women's Health Inc.

Aspira Women's Health Inc. (AWH) Mission Statement

Aspira Women's Health Inc. (AWH) is dedicated to pioneering innovative diagnostic solutions for gynecologic cancers, focusing specifically on ovarian cancer. Their mission centers around improving early detection and treatment outcomes for women around the world.

Core Values

• Integrity: Upholding the highest standards of ethics and transparency in all dealings.
• Innovation: Committing to continuous improvement and advancement in diagnostic technology.
• Compassion: Prioritizing the health and well-being of women through dedicated service.
• Collaboration: Building partnerships with healthcare providers, researchers, and patients.

Strategic Goals

The strategic goals of AWH include:

• Enhancing the accuracy of ovarian cancer diagnostic tests.
• Expanding market reach and accessibility of products.
• Investing in research and development for new diagnostic technologies.
• Fostering educational initiatives to raise awareness about ovarian cancer.

Financial Overview

For the fiscal year ending December 31, 2022, Aspira Women's Health reported the following financial figures:

Market Impact

Aspira Women's Health Inc. aims for robust market growth, focusing on the following statistics:

• The global ovarian cancer diagnostics market is projected to reach approximately $1.5 billion by 2025.
• According to the American Cancer Society, about 19,880 women will receive a new diagnosis of ovarian cancer in 2023.
• The five-year survival rate for ovarian cancer currently stands at 47% when detected early.

Commitment to Research and Development

AWH allocates a significant portion of its budget towards R&D, with a commitment of:

Community Engagement

Aspira Women’s Health is actively involved in community outreach through:

• Partnerships with cancer advocacy groups.
• Educational campaigns on the importance of early detection.
• Participation in health fairs and screenings to promote ovarian cancer awareness.

How Aspira Women's Health Inc. (AWH) Works

Company Overview

Aspira Women's Health Inc. (AWH) is a women's healthcare company focused on developing and commercializing diagnostic tests that can help in the early detection of gynecological cancer, notably ovarian cancer.

Financial Performance

For the fiscal year ended December 31, 2022, AWH reported the following financial highlights:

Products and Services

AWH specializes in the following key products:

• OVA1: A diagnostic blood test that assesses the likelihood of ovarian cancer.
• Overa: A follow-up test that helps to confirm or rule out the risk of ovarian cancer.
• Other emerging diagnostic platforms aimed at women's health.

Market and Growth Opportunities

The global market for ovarian cancer diagnostics is projected to grow. Key statistics include:

Partnerships and Collaborations

AWH focuses on strategic partnerships to enhance its market presence:

• Collaboration with clinical laboratories for expanded testing availability.
• Partnerships with healthcare providers to integrate diagnostic solutions into patient care.
• Engagement with research institutions for developing innovative diagnostic technologies.

Regulatory and Compliance

AWH operates under strict regulatory standards. Key points include:

• Compliance with FDA regulations for diagnostic tests.
• Quality assurance measures for laboratory operations.
• Adherence to HIPAA regulations for patient data protection.

Recent Developments

Recent milestones as of 2023:

• Received Breakthrough Device Designation from the FDA for Overa.
• Expansion of distribution agreements across North America.
• Launch of educational campaigns about ovarian cancer awareness.

Conclusion

Aspira Women's Health Inc. continues to focus on advancing its diagnostic capabilities while aiming for sustainable financial growth. Their commitment to women's health is reflected through ongoing innovations and partnerships in the industry.

How Aspira Women's Health Inc. (AWH) Makes Money

Clinical Diagnostics

Aspira Women's Health Inc. primarily generates revenue through its innovative diagnostic tests. These tests are designed to provide critical information regarding women's health, particularly in relation to gynecological conditions.

The company's flagship product, the Aspira Synergy, is a proprietary test that analyzes ovarian cancer risk. In 2022, Aspira reported revenues of approximately $6.8 million from its diagnostic services.

Product Revenue Breakdown

Partnerships and Collaborations

Aspira Women's Health has engaged in various partnerships to enhance its product offerings and market reach. Notably, a collaboration with major healthcare providers has been essential for driving test adoption.

In 2023, the company announced a partnership with LabCorp, which is expected to increase accessibility to its diagnostic tests. Projected revenue from this collaboration is estimated to be around $3 million in the first year.

Reimbursement Strategies

Aspira focuses heavily on obtaining reimbursement for its diagnostic tests from insurance providers. The company has made significant strides in securing Medicare and Medicaid coverage, which provides a substantial revenue stream.

• The average reimbursement rate for the Aspira Synergy test is approximately $800.
• As of Q2 2023, the company had achieved a reimbursement rate approval for 80% of its test claims.

Research and Development (R&D)

Aspira is committed to continuous innovation and expansion of its product line. In 2022, the company invested $4 million in R&D, aiming to introduce new tests and improve existing ones.

The investment is expected to yield additional revenue streams with the introduction of new diagnostic platforms projected for 2024.

Market Presence and Sales Channels

Aspira Women's Health has established a comprehensive market presence through direct sales and online platforms. The company operates through a network of medical professionals and clinics to deliver its services.

In 2022, 60% of revenue generated came from direct sales to healthcare facilities, while 40% was attributed to online and telehealth services.

Financial Performance

In reviewing the overall financial performance of Aspira Women's Health:

Future Outlook

With a growing focus on women's health, market analysts project Aspira Women's Health is set to capitalize on increasing demand. The anticipated market growth for gynecological diagnostics is expected to reach $4 billion by 2025.

With strategic partnerships and innovative product lines, the company's revenue growth is projected to be around 40% annually over the next few years.